Biotech billionaire Patrick Soon-Shiong has already laid the foundation for a big IPO to help finance his low-profile oncology R&D player Conkwest. Now he's moving closer to getting his high-profile personalized drug-finding company NantHealth on the market as well.
Biotech billionaire Patrick Soon-Shiong is pumping $71 million into Conkwest as it preps a move to go public in a $172.5 million IPO.
Patrick Soon-Shiong thinks he can beat CAR-Ts in the clinic. And after quietly taking control of a small biotech named Conkwest, the biotech billionaire is now floating a $172.5 million IPO in a sizzling hot market to raise new funds for the midstage program that lies ahead.
It seems not a month goes by without billionaire entrepreneur Patrick Soon-Shiong striking a deal to expand his sprawling family of cancer-focused startups. This time, the recently launched NantCell has raised $75 million in equity, pressing forward in immuno-oncology with some in-licensed treatments.
Sorrento Therapeutics, a frequent partner of billionaire biotech entrepreneur Patrick Soon-Shiong, launched a new subsidiary to advance its take on CAR-T therapies for cancer, taking a page from its patron as it tosses more and more irons in the R&D fire.
NantWorks, the nebulous empire of biotech billionaire Patrick Soon-Shiong, is handing over $90 million to partner Sorrento Therapeutics in exchange for a Phase III cancer drug heralded as a successor to the blockbuster Abraxane.
Billionaire entrepreneur Patrick Soon-Shiong has raised $100 million for one of the many offshoots of his NantWorks conglomerate, working to duplicate the success of the targeted cancer drug that helped build his empire.
Billionaire biotech entrepreneur Patrick Soon-Shiong is expanding his company's relationship with Sorrento Therapeutics, promising $110 million in cash and equity in exchange for the rights to some cancer-fighting immunotherapies.
NantHealth, an arm of billionaire physician and biotech entrepreneur Patrick Soon-Shiong's empire, promises to improve cancer diagnostics through a marriage of genomics and high-speed computing. But behind its sleek marketing campaign and Soon-Shiong's bravura, the company is misleading customers and putting patients at risk, according to a lawsuit filed by two former employees.
Billionaire physician and biotech entrepreneur Patrick Soon-Shiong has launched a company devoted to immuno-oncology, licensing a treatment from Amgen to get rolling in the field.